Global Bendamustine Market Outlook 2022

Bendamustine is a chemotherapy medication used in the treatment of chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin's lymphoma. It is given by injection into a vein.
Market competition is intense. Teva, Eisai, Eagle Pharmaceuticals, MundiPharma, Mylan, Natco Pharma, Emcure, etc. are the leaders of the industry, with Teva occupies the major markets share of over 83% in 2018.

The global Bendamustine market was valued at US$ 799.5 million in 2020 and is expected to reach US$ 750.5 million by the end of 2027, growing at a CAGR of -0.9% during 2021-2027.
This report focuses on Bendamustine volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Bendamustine market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Bendamustine Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
25mg Injection
100mg Injection
Others

Segment by Application
Chronic Lymphocytic Leukemia
Multiple Myeloma
Non-Hodgkin's Lymphoma

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Teva
Eisai
Eagle Pharmaceuticals
MundiPharma
Mylan
Natco Pharma
Emcure
Miracalus Pharma